Adrian Spooner is a consultant and is a dual qualified practising solicitor and pharmacist and a member of the Royal Pharmaceutical Society and registered with the General Pharmaceutical Council.

He specialises in life science, pharmaceutical and healthcare legal work, mainly for manufacturers and others in the pharmaceutical and healthcare product supply chain with particular expertise on commercial, regulatory and intellectual property law.

Adrian also advises suppliers of services to the healthcare industry and potential investors in the sector.  He has considerable experience advising both innovative and generic manufacturers on protecting or entering existing and potential markets, the life science and pharmaceutical market generally and routes of supply, for example, e-commerce and healthcare.

Adrian also provides advice in relation to pharmaceutical, medical device and biotechnology legislation and regulatory control. He has advised for many years on the structure and operation of UK National Health Service and UK healthcare profession practice and regulation in both primary and secondary care markets. He also continues to practice as a pharmacist.

Adrian works across the legal practice and provides advice on contentious and non-contentious issues that arise in a number of our practice areas including corporate, commercial and intellectual property and dispute resolution. He has advised on numerous corporate and commercial transactions including company and product acquisitions and disposals, market placing and other fundraising exercises.

Award Mouse thought multimedia interface book medal screen monitor
  • Advising clients on the EU pharmaceutical legislative review including the introduction of patent early working provisions and related patent and data exclusivity controls.
  • Advising on a new scheme for generic medicines supply and reimbursement.
  • Advising a generic pharmaceutical company on a patent infringement dispute involving a major antidepressant medicine.
  • Advising on the commercial, regulatory and intellectual property aspects on various AIM flotation’s and product acquisitions and disposals in the pharmaceutical and medical devices sector.
  • Advising in judicial review proceedings to prevent the release of confidential information regulatory data relating to plant protection products.
  • Advising and co-ordinating multijurisdictional UK, EU and non-EU pharmaceutical regulatory compliance and due diligence in relation to a £700 million acquisition of a major pharmaceutical company.
  • Advising on UK/EU pharmaceutical regulatory and commercial matters related to the requirements for market entry of a new asthma medicine, including regulatory requirements for approval, marketing and associated infrastructure and UK pricing policy and pricing and reimbursement.
  • Advising on the ownership and rights arising from biotechnology research collaboration concerned with the development of a class of oncology medicine and associated delivery system.
  • Advising a major UK pharmaceutical wholesaler on compliance with generic and branded statutory price control measures and new statutory and voluntary price control measures recently introduced.
  • Advising on the use of e-pharmacy and the supply of EHC and other products.
  • Advising on a number of purchases of NHS retail pharmacy companies.
  • Advising a UK-based medical device and pharmaceutical company on borderline issues under Directive 2001/83 and Directive 93/42 and associated UK legislation relating claims and mode of action of the relevant treatment. This work included strategic advice relating to third party rights and potential regulator action.
  • Acting for a major public affairs company in relation to a report and development of pharmaceutical client based public affairs programme relating to pharmaceutical regulation, pharmacovigilance and health technology assessment and associated pharmaceutical product liability issues.
  • Advising UK research tool developer on application of technology in the pharmaceutical sector and relevant IP and regulatory issues relevant to life cycle management.
  • Advising on the Food Supplements Directive and UK regulation and control of food supplements in relation to potential product acquisition by client healthcare company.
  • Advising on UK NHS regulations dealing with primary care pharmaceutical pricing and reimbursement and oxygen supplies and potential public law action and contractual issues.
  • Advising in relation to a project to obtain a marketing authorisation for a pharmaceutical company in the EU/UK including data package protection, patent and third party rights issues.
  • Advising a major company in relation to pharmaceutical supply routes, NHS, pharmaceutical professional and medicines control in the UK in relation to a major contentious health and safety matter.
  • Advising on a pharmaceutical prescription only switching project in the EU including advice on procedure, classification and intellectual property protection and advice on third party supply contractual matters.
  • Advising a US-based company on representations to the UK MHRA on borderline issues and labelling of a medical device.
  • Advising on MBO of UK specials pharmaceutical manufacturer including manufacturing regulation and pricing issues.
  • Advising on a research and development, marketing authorisation and manufacturing project in the plant protection product sector including advice on generation, ownership and use of IP rights and related regulatory issues.


  • The EU Pharmaceutical Review: An essential business guide, PJB/Informa publications, 2005.


  • Primary care pharmaceutical price control in the UK: EGA Conference, London, 2005.
  • Pharmaceutical Pricing and reimbursement in the EU: C5 Conference, Zurich, 2007.
  • NHS Pharmaceutical Services - control of entry, the Galbraith report and the White Paper, London, 2008.
  • Legal issues in fundraising exercises in the biotech sector: Genesis Biotech Seminar for British-Israeli Chamber of Commerce, London, 2008.
  • Association of British Healthcare Industries Code of Business Practice Complaints Procedure and Sanctions: ABHI Code of Business Practice Seminar, Leeds, 2010.
  • Biotechnology in the EU: Chilean Trade Delegations, London, 2010.


  • University of Birmingham, L.P.C., 1995
  • University of Leicester, 1994
  • Liverpool John Moores University, B.Sc., 1989


  • England and Wales, 1998
  • Recommended in The Legal 500 UK 2017 for Pharmaceuticals and biotechnology
  • Recommended in The Legal 500 UK 2015 for Pharmaceuticals and biotechnology

{{}} {{insights.type}} {{insights.contentTypeTag}}
{{blog.title}} {{blog.source}}
Award Mouse thought multimedia interface book medal screen monitor